HDAX is developing small molecules that utilize a novel two-site binding mechanism to target HDAC6, a key protein involved in microtubule stability and inflammatory processes. This approach addresses the limitations of conventional drug design by enhancing efficacy and safety for treating neuropathies and cardiovascular diseases.
Funding
$5.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
FTIFounders
Product
Problem
Conventional drug design often struggles to effectively target disease-driving proteins, leading to limited efficacy and challenges in translating research into meaningful treatments for patients. This is particularly true for complex targets like HDAC6, where achieving both high potency and selectivity has been difficult.
Solution
HDAX is developing a new class of small molecule therapeutics that target HDAC6 using a proprietary two-site binding mechanism. This innovative approach enhances both the efficacy and safety profiles of their drug candidates. By selectively modulating HDAC6, HDAX aims to address the limitations of first-generation medicines and unlock the full therapeutic potential of HDAC6 inhibition for diseases with limited treatment options. Their technology broadens dosing regimens and improves pharmacokinetics, potentially leading to life-changing treatments for debilitating diseases.
Target Audience
The primary target audience includes patients suffering from neuropathies, cardiovascular diseases, and other conditions where HDAC6 modulation can provide therapeutic benefit, as well as pharmaceutical companies seeking innovative drug candidates with improved efficacy and safety profiles.
Features
- Novel 2-site binding mechanism for enhanced HDAC6 selectivity and potency
- Improved drug-like features, including enhanced efficacy, pharmacokinetics, and safety profile
- Potential for multi-indication applications due to HDAC6's involvement in cytoskeleton dynamics, microtubule stability, and inflammatory processes
- Small molecule therapeutics designed to overcome the limitations of traditional drug design approaches